Gayatin, Krizzia Jane P.

HRN: 19-92-03  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/18/2022
CEFUROXIME 500MG (TAB)
10/18/2022
10/25/2022
ORAL
500mg
Q12
S/P Pelvic Lap
Waiting Final Action 

Indication:  Prophylaxis    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: